Skip to main content

Table 5 Association of Behçet’s disease (BD) characteristics with human leukocyte antigen (HLA)-B*51 and rs76546355

From: Characterization of the major histocompatibility complex locus association with Behçet’s disease in Iran

 

HLA-B*51

rs76546355

Characteristic

B*51 +

B*51

P -values

OR (95% CI)

AA + GA

GG

P -values

OR (95% CI)

Male sex, %

72.2

67.0

1.54 × 10−1

 

54.4

48.6

9.07 × 10−2

 

Age at onset, years, mean ± SD

26.3 ± 9.1

25.5 ± 10.2

3.02 × 10−1

 

26.0 ± 9.1

25.8 ± 10.4

7.25 × 10−1

 

Genital aphthosis, %

62.8

61.2

6.96 × 10−1

 

66.5

55.6

1.05 × 10 −3

1.59[1.20-2.09]

Skin lesions, %

59.7

53.7

1.39 × 10−1

 

56.7

52.7

2.38 × 10−1

 

Ophthalmologic manifestations, %

63.0

62.1

8.23 × 10−1

 

59.2

61.6

4.88 × 10−1

 

Joint manifestations, %

33.9

28.2

1.31 × 10−1

 

32.0

28.9

3.32 × 10−1

 

Neurological manifestations, %

5.9

6.6

2.03 × 10−1

 

5.6

4.4

8.85 × 10−1

 

Vascular involvement, %

5.3

7.5

7.36 × 10−1

 

6.3

6.0

4.35 × 10−1

 

Gastrointestinal manifestations, %

3.3

3.1

8.79 × 10−1

 

3.6

4.4

5.28 × 10−1

 

Positive pathergy test, %

51.8

40.8

7.34 × 10−3

1.56 (1.13, 2.16)

50.2

37.5

2.31 × 10 −4

1.69 (1.28, 2.23)

Positive family history of BD, %

10.3

5.1

2.35 × 10−2

2.16 (1.09, 4.27)

10.9

4.6

1.59 × 10 −3

2.52 (1.40, 4.58)

  1. The study of rs76546355 was performed in all BD patients (n = 973) while the HLA-B*51 study was conducted in the subset of patients allelotyped for HLA-B (n = 681, of which 454 patients were positive for B*51 and the remaining 227 cases were B*51-negative). Significant P-values after Bonferroni correction (P ≤4.17 × 10−3) are highlighted in bold. The odds ratio (OR) and 95% CI are indicated for nominally significant associations.